Form 4: Verastem Director John Johnson Receives Stock Options and Restricted Stock Units

Director John Johnson of Verastem, Inc. received stock options and restricted stock units (RSUs) on June 18, 2024, according to a Form 4 filing with the SEC.

Summary

• John Johnson, a director of Verastem, Inc., received 12,500 stock options with an exercise price of $3.27 and 8,333 restricted stock units (RSUs) on June 18, 2024.
• The RSUs represent the contingent right to receive one share of Common Stock each.
• Both the stock options and RSUs vest in twelve equal monthly installments starting in June 2024 and ending in April 2025, with the final installment vesting no later than May 31, 2025, or the day before the 2025 Annual Meeting of Stockholders, contingent upon continued service as a director.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. The sentiment is neutral to slightly positive.

Positives

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.
• The vesting schedule encourages continued service as a director.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain talent, particularly for directors and key executives. These grants align the interests of management with those of shareholders, incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in publicly traded companies, especially in the biotech sector.
• Vesting schedules, like the monthly vesting described, are common to ensure continued service and alignment with long-term company goals.
• Comparable companies such as Blueprint Medicines or Relay Therapeutics also utilize equity-based compensation for their board members.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the director's interests with the company's performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates